A NEW prostate cancer drug for late-stage patients with few treatment options has yielded early trial results described today as "extremely exciting".
Half the men taking the drug abiraterone experienced a substantial drop in blood levels of PSA (prostate specific antigen), the biomarker used to track prostate cancer.
Omega Replica Watches The 47 men recruited for the Phase II trial in the UK and US all had late-stage cancers that were resistant to traditional hormone treatments. In almost every case, the cancer had spread to the bones.
Zenith Replica Watches All had received docetaxel, the only currently approved chemotherapy drug known to benefit patients with advanced prostate cancer.
"Docetaxel is an important drug but it extends life for an average of just two to three months, so there is a desperate need to improve treatment options for late-stage prostate cancer patients," said chief investigator Dr Johann de Bono, from the Institute of Cancer Research and Royal Marsden Hospital, based in London and Surrey.
paper bag printing "In this trial, abiraterone shrank or stabilised men's cancers for an average of almost six months, which is a very impressive result."
About three-quarters of men experienced a drop in PSA levels.
About three-quarters of men experienced a drop in PSA levels.
Other articles:
http://www.dcnk.net/China-Faw-Group-sets-00-sale.htmlhttp://www.pilotlocator.net/blog.php?user=mywatches&blogentry_id=169
